Phase II study of CI-958 in colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 2, 1999, Pages 162-164

  Shields, Anthony F ^a,b,c   Philip, Philip A ^a,b   LoRusso, Patricia M ^a,b   Ferris, Ann M ^a,b   Zalupski, Mark M ^a,b  

^a DETROIT MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

CI 958; Colon; Phase II; Rectal

Indexed keywords

DEXAMETHASONE; FLUOROURACIL; LEDOXANTRONE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG FEVER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDAZOLES; INTERCALATING AGENTS; LEUKOPENIA; MALE; MIDDLE AGED;

EID: 0032948092     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050878     Document Type: Article

References (10)

1. Cohen AM, Minsky BD, Schilsky RL (1997) Colon cancer. In DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice in oncology, 5th edn. JB Lippincott, Philadelphia. p 1144
2. Donchower R, Grove W, Whitfield L, Grochow L, Ettinger D, Forastiere A, McGuire W, Kowal K, Rowinsky E (1993) Successful use of pharmacologically guided dose escalation (PGDE) in a phase I trial of CI-958. Proc Am Soc Clin Oncol 12: 139
3. Fleming TR (1982) One sample multiple testing procedure for phase II clinical trials. Biometrics 38: 148
4. Fry DW, Besserer JA (1988) Biochemical pharmacology and DNA-drug interactions by CI-958, A new antitumor intercalator derived from a series of substituted 2H-[1]benzothiopyrano[4,3,2-cd]indazoles. Mol Pharamacol 33: 84
5. Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics, 1998. CA Cancer J Clin 48: 6
6. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, Macdonald JS (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 13: 1303
7. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207
8. Pitot HC, Wender DB, O'Connell MJ, Shroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling RJ, Levitt R, Windschitl HE (1997) Phase II trial of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 15: 2910
9. Showalter HDH, Angelo MM, Berman EM, Kanter GD, Ortwine DF, Ross-Kesten SG, Sercel AD, Turner WR, Werbel LM, Worth DF, Elslager EF, Leopold WR, Shillis JL (1988) Benzothiopyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents. J Med Chem 31: 1527
10. Trump D, Freiha F, Woolley P, Smith D, Hofacker J, Quinn N, Carlson L, Grove W (1996) CI-958 Phase 2 study in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 15: 253